Objective: Despite recent advancements in targeted therapy and immunotherapies, prognosis for metastatic melanoma patients remains extremely poor. Development of resistance to previously effective treatments presents a serious challenge and new approaches for melanoma treatment are urgently needed. The objective of this study was to examine the effects of telmisartan, an AGTR1 inhibitor and a partial agonist of PPARγ, on melanoma cells as a potential agent for repurposing in melanoma treatment. Methods: Expression of AGTR1 and PPARγ mRNA in melanoma patient tumor samples was examined in publicly available datasets and confirmed in melanoma cell lines by qRT-PCR. A panel of melanoma cell lines was tested in viability, apoptosis and metabolic assays in presence of telmisartan by flow cytometry and immunocytochemistry. A cytotoxic effect of combinations of telmisartan and targeted therapy vemurafenib was examined using the Chou-Talalay combination index method. Results: Both AGTR1 and PPARγ mRNA were expressed in melanoma patient tumor samples and decreased compared to the expression in the healthy skin. In vitro, we found that telmisartan decreased melanoma cell viability by inducing cell apoptosis. Increased glucose uptake, but not utilization, in the presence of telmisartan caused the fission of mitochondria and release of reactive oxygen species. Telmisartan altered the cell bioenergetics, thereby synergizing with vemurafenib in vitro, and even sensitized vemurafenib-resistant cells to the treatment.
Introduction
Melanoma is one of the most aggressive malignancies. If left untreated, patients with distant metastasis have a median survival of 6-9 months. In the last decade, a dramatic improvement in the survival of melanoma patients has been achieved with neutralizing antibodies targeting immune checkpoints (anti-PD-1 and anti-CTLA-4 immunotherapy) and via targeted BRAF and MEK inhibition 1 . However, mortality rates remain high in advanced-stage patients 2 . Fifty percent of melanoma tumors carry the BRAF V600E mutation, but despite the dramatic initial effects of BRAF inhibitors in clinical settings, patients eventually experience relapse, suggesting that combination therapies may be needed to overcome resistance. In most developed countries, patients with BRAF-mutated melanoma receive a combination of BRAF and MEK inhibitor therapies, which has high response rates; nevertheless, the median time to relapse is less than 10 months 3 . Both genetic and epigenetic changes contribute to the resistance to targeted therapy. Better understanding of the mechanisms of resistance is needed as well as strategies to overcome them. BRAF inhibitors suppress glycolysis 4 , yet the subsequent increase in oxidative metabolism limits their efficacy 5 . Many melanoma driver genes control cellular metabolism. Heterogeneity in genetic driver profiles and mitochondrial capacity can influence the effectiveness of the treatment 6 . Therefore, agents that target different aspects of cell metabolism could improve the effects of melanoma chemotherapy and BRAF inhibitor efficacy.
Development of new drugs is costly, and the approval for their use and translation into clinics often takes between 10 and 15 years. In contrast, repurposing of drugs already approved for other uses (drugs that have been tested in humans, and for which information regarding pharmacology, formulation, and potential toxicity is available) enables their quick translation into clinical trials and integration into healthcare 7 . Recently, it has been recognized that therapy for chronic diseases can have an impact on the progression and outcome in cancer patients. In this study, we examined the effects of telmisartan on melanoma cells. Telmisartan is an angiotensin receptor 1 (AGTR1) inhibitor and a partial agonist of peroxisome proliferator-activated receptor γ (PPARγ). Human melanoma tissues express both angiotensin II and AGTR1, and inhibition of AGTR1 in mouse models of melanoma was shown to inhibit tumor growth by decreasing the tumor vessel density 8 . PPARγ is a nuclear receptor that is an important regulator of lipid and glucose metabolism 9 . Activation of PPARγ in melanoma cells has growthinhibitory effects 10, 11 via the induction of cell cycle arrest. PPARγ agonists have also been shown to have pro-apoptotic PPARγ-independent effects 12 . In recent years, telmisartan has been reported to have anticancer effects in in vitro and in vivo models of various solid tumors [13] [14] [15] [16] [17] , but its effects on melanoma have not yet been investigated. Therefore, we hypothesized that telmisartan through its dual activity, as an AGTR1 inhibitor and PPARγ agonist with possible extrareceptor effects, can have an anti-melanoma activity that is superior to that of agents with single activity. In this study, we have found that telmisartan induces apoptosis in both BRAF V600E mutated and wild-type melanoma cells, and that it causes mitochondrial fragmentation and the generation of free radicals. The alteration of cellular energetics by telmisartan enabled it to synergize with the BRAF inhibitor vemurafenib, thereby improving the response in a vemurafenib-resistant melanoma cell line. Collectively, we report that the clinically available antihypertensive agent telmisartan can potentially be repurposed as an anti-cancer therapeutic for melanoma treatment.
Materials and methods

In silico gene expression analysis
For the analysis of PPARγ and AGTR1 expression in melanoma tumors, the datasets GSE7553, GSE19234, GSE3189, GSE46517, and GSE8401 were uploaded to GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r/), and the samples were divided into the following groups: normal skin, melanoma in situ, primary melanoma, and metastatic melanoma. Sample values were plotted in Prism 7 (Graphpad) and analyzed using one-way ANOVA and Dunnett's multiple comparisons test. For the survival analysis of data from the GSE19234 dataset, the samples were divided into the PPARγ-high and PPARγ-low expression groups (the 2 × SD value was used for determining the cut-off) and analyzed using the log-rank (Mantel-Cox) test.
Cell culture, drug treatments and viability assays
Human melanoma cell lines with the BRAF V600E mutation A375 and 518a2 and the BRAF wild-type melanoma cell lines HTB140 and FemX-1 were cultured in RPMI 1640 medium with 2 g/L glucose (Sigma-Aldrich, R8755, Taufkirchen, Germany), 10% FBS, and antibiotics. The A375 cell line was procured from ATCC. The FemX-1 cell line 18 was a kind gift from Dr Nikola Vujanović. The 518a2 and HTB140 cell lines were kind gifts from Dr Milica Pešić. All the cell lines were tested for the presence of mycoplasma by PCR 19 , and if required, treated with MycoXpert (Capricorn Scientific, Ebsdorfergrund, Germany). Vemurafenib (Zelboraf), telmisartan, pioglitazone, and losartan-potassium were provided by the Medicines and Medical Devices Agency of Serbia as pure substances. N-acetyl-L-cysteine, L-glutathione, 2-deoxy-D-glucose, and apocynin were obtained from Sigma-Aldrich. The cytotoxicity of the drugs was determined by performing the MTT assay (Sigma-Aldrich) in 96-well plates, at a density of 5,000 cells/well, with at least three biological repeats. After 72 h of incubation with the drugs, the absorbance of the samples was measured at 570 nm on a Multiskan EX reader (Thermo Labsystems, Helsinki, Finland). IC 50 values (μM) were determined from the doseresponse curves as the concentration of the compound causing a 50% decrease in MTT reduction, compared to the control (DMSO)-treated samples.
Annexin/PI assay
Quantitative analysis of apoptotic and necrotic cell death induced by 50 μM telmisartan or 100 μM pioglitazone was performed using an Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions (BD Biosciences, Franklin Lakes, USA). After 24 or 48 h of treatment with the drugs, the A375 cells were trypsinized, washed twice with ice-cold PBS, and resuspended in 200 μL of binding buffer[10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl 2 ]. Next, 2 × 10 5 cells were stained with Annexin V-FITC and PI. After 15 min of incubation at room temperature in the dark, the cells were analyzed using a FACS Calibur Becton Dickinson (San Jose, USA) flow cytometer and the Cell Quest computer software.
Cell cycle analysis
A375 and A375R cells were treated for 72 h with 0.5 μM vemurafenib, and quantitative analysis of the cell cycle phase distribution was performed by flow cytometry (Calibur Becton Dickinson flow cytometer and BD Cell Quest computer software). The DNA content in fixed, RNaseA (1 mg/mL)-treated cells was stained with 400 mg/mL propidium iodide (PI), and 20,000 events were counted.
Flow cytometric analysis of phospho-p38 and cleaved caspase 3
After 24 h (for phospho-p38) or 48 h of treatment (for cleaved caspase 3) with 50 μM telmisartan, the cells were trypsinized, fixed, permeabilized, and then blocked with 1.5% BSA in PBS. Cells were then incubated with PE mouse anti-p38MAPK pT180/pY182 (612565, BD Biosciences, Franklin Lakes, USA) antibody or FITC rabbit anti-active caspase-3 antibody (51-68654x, BD Biosciences) for 1 h in the dark at room temperature. After washing, the cells were resuspended in PBS and analyzed using a FACS Calibur Becton Dickinson flow cytometer.
Detection of intracellular ROS and mitochondrial potential
For the detection of ROS, 2 × 10 5 A375 or HTB140 cells were treated with 50 μM telmisartan, 100 μM pioglitazone, 100 μM losartan, or 50 μM telmisartan in the presence of 1 mM L-GSH, 10 mM NAC, or 100 μM apocynin for 24 h. The cells were stained with 50 μM H2DCFDA (D3999, Thermo Fischer Scientific, Schwerte, Germany) for 30 minutes at 37°C. For the measurement of the mitochondrial potential, A375 cells were treated with 50 μM telmisartan or 100 μM pioglitazone for 24 h, and then stained with 2.5 μg/mL of Rhodamine123 (R302, Thermo Fischer Scientific) in PBS for 1 h at 37°C, and analyzed using a FACS Calibur Becton Dickinson flow cytometer.
Glucose uptake and consumption and lactate production
Glucose uptake was measured by flow cytometry as described in a previous report 20 . A375 cells were pretreated for 1 or 24 h with 50 μM telmisartan or 50 μM pioglitazone and incubated with 20 μM 2-NBDG, a fluorescent glucose analog (N13195, Thermo Fischer Scientific), for 1 h at 37°C.
For measuring the glucose consumption, 10 × 10 5 A375 or HTB140 cells were seeded into six-well plates in duplicate. After 24 h, the cells were collected (from duplicate wells) for protein extraction at the 0 h time point, and the cells in the test wells were treated with 50 μM telmisartan or pioglitazone in RPMI 1640 medium containing 2 g/L glucose (Sigma, R8755, Taufkirchen, Germany). After 24 h, the medium was collected and glucose concentration was measured using a Cobas bioanalyzer C111 (Roche, USA). The remaining cells were collected for protein extraction at the 24 h time point. The protein content in the cells was extracted using RIPA buffer, and the protein concentration was measured using the Qubit Fluorometer and Qubit Protein assay kit (Q33211, Molecular Probes, Eugene, USA). Glucose consumption was calculated by subtracting the amount of glucose present in the medium after 24 h of incubation from the amount of glucose initially present in the medium (2 g/L), and normalized to the area under the curve for cell growth per hour. The experiment was repeated thrice and statistical analysis was performed using two-way ANOVA and Tukey's multiple comparisons test.
Lactate consumption was measured using an extracellular acidification assay kit (ab197244, Abcam, Cambridge, UK), according to the manufacturer's instructions. A375 or HTB140 cells were treated with 50 μM telmisartan or pioglitazone for 24 h and then trypsinized; equal numbers of cells were resuspended in 100 μL of resuspension buffer. The cell suspensions were loaded into 96-well black polystyrene plates (237105, Nunc, Schwerte, Germany), and 10 μL of Glycolysis Assay reagent was added to each sample. Respiration buffer plus the reagent served as the blank control. Signals were measured at 2-min intervals for 120 minutes with an Ex/Em of 380/615 using a Tecan Infinite m1000Pro reader (Tecan, Zurich, Switzerland) in Dual TR-F mode with a 30 μs delay and 100 μs gate time. Blank controlcorrected intensity values (AU) were plotted against time in minutes. The experiment was repeated twice.
Immunocytochemistry for TOM20 and MitoTracker Red CMXRos staining
Formaldehyde-fixed melanoma cells were stained with mouse anti-Tom20 antibody (F-10, sc-17764, Santa Cruz biotechnology, Heidelberg, Germany) and Alexa Fluor 488 goat anti-mouse antibody (R37120, Thermo Fischer Scientific), counterstained with DAPI (Sigma), and imaged using an epi-fluorescent microscope (Olympus, Japan) with a 60 × lens. For staining of the active mitochondria, the melanoma cells were stained with 100 nM MitoTracker Red CMXRos (#9082, Cell Signaling Technology, Frankfurt, Germany) for 20 minutes at 37°C, fixed with ice-cold methanol, and imaged using an epi-fluorescent microscope.
Analysis of gene expression by real-time PCR
RNA was isolated from melanoma cells using the TRI REAGENT® BD kit (Sigma-Aldrich). cDNA synthesis from total RNA (2 μg) was performed using random primers and MultiScribe TM Reverse Transcriptase from the High-Capacity cDNA Reverse Transcription kit (50 U/μL, Applied Biosystems, Schwerte, Germany). RT-PCR was performed with Maxima SYBR green/ROX qPCR master Mix (K00221, Thermo Scientific). The primers used were as follows: PPARγ forward 5′-GGCTTCATGACAAGGGAGTTTC-3′ and PPARγ reverse 5′-AACTCAAACTTGGGCTCCATAAAG-3′; Agtr1 forward 5′-AACAGCTTGGTGGTGATCGTC-3′ and Agtr1 reverse 5′-CATAGCGGTATAGACAGCCCA-3′. The reactions were performed using the ABI Prism 7,700 Sequence Detection System (Applied Biosystems). The expression level data were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression, analyzed by the deltadelta-Ct method, and represented as the means ± SEMs of three independent experiments.
Drug interaction analysis
To determine the synergistic, additive, or antagonistic effects of the drug combinations, we performed the combination index method described by Chou and Talalay 21 , using the CalcuSyn software (version 2.0 Biosoft, Cambridge, UK). This method takes into account both the potency of the drug [median dose (Dm) or IC 50 ] and the shape of the dose-effect curve (the m value) to calculate the combination index (CI). A CI equal to 1 indicates an additive effect; a CI less than 1 indicates synergy. With the use of the CalcuSyn software, synergy is further refined as synergism (CI = 0.3-0.7), strong synergism (CI = 0.1-0.3), and very strong synergism (CI < 0.1). Isobolograms and heat maps were plotted using the Prism 7 software.
Results
Expression of PPARγ and AGTR1 receptors in melanoma patient samples and melanoma cell lines
We first performed an in silico analysis of the available gene expression databases of melanoma tumors in the GEO repository for the expression of two telmisartan receptors: PPARγ and AGTR1. We examined the Talantov 22 , Kabbarah 23 , Riker 24 , Xu 25 , and Bogunovic 26 datasets ( Figure  1 ). PPARγ mRNA expression was decreased in primary melanoma, compared to the uninvolved skin ( Figure 1A , 1C), while there was no difference between the PPARγ mRNA expression in primary tumors and metastatic lesions ( Figure 1B-1D ). In the Bogunovic data set 26 , which includes the clinical outcome data for metastatic patients, we found that there were very few tumors expressing high PPARγ levels, and they were associated with better survival (log-rank value not available due to small sample size in the PPARγ-high expression group, Figure 1E and 1F). AGTR1 mRNA expression also decreased in primary tumors, compared to uninvolved skin (Figure 2A and 2B) . Additionally, in some data sets, it further decreased in metastatic lesions ( Figure  2C ), while in others, there was no difference between the AGTR1 mRNA expression in primary and metastatic tumor samples ( Figure 2B and 2D ). In the Bogunovic data set 26 , only 3 AGTR1 mRNA values were outside of the standard deviation range; hence, the survival analysis was not performed ( Figure 2E ). Therefore, there is a trend of decrease in case of both the PPARγ and AGTR1 mRNA expression with the progression of melanoma. We then screened the mRNA expression of PPARγ and AGTR1 in a panel of four human melanoma cell lines: A375, 518a2, HTB140, and Fem-X. Expression of PPARγ ( Figure 1G ) and AGTR1 mRNA ( Figure 2F ) was normalized to GAPDH expression and was detectable in both the BRAF WT cell lines (FemX-1 and HTB140) and BRAF V600E mutant cell lines (A375 and 518a2). The FemX-1 cell line showed the lowest expression of both genes, while 518a2 showed the highest expression.
Telmisartan reduces melanoma cell viability through the induction of apoptosis
Next, we examined the melanoma cell viability in vitro in the presence of telmisartan and compared it with that observed after treatment with the PPARγ agonist pioglitazone and AGTR1 inhibitor losartan. Melanoma cells were treated with increasing concentrations of the drugs for 72 h, and their viability was measured by the MTT assay (Figure 3A-3C ).
Telmisartan dose-dependently reduced melanoma cell viability; its performance was comparable to and better than that of pioglitazone at the same concentration in all the tested cell lines. On the contrary, the direct AGTR1 antagonist losartan did not show significant effects (best-fit IC 50 values; Figure 3D ). Interestingly, cells with the BRAF V600E mutation (A375 and 518a2 cells) had lower IC 50 values for telmisartan than BRAF WT cells (FemX-1 and HTB140) ( Figure 3A , P < 0.0001 by two-way ANOVA). We next examined the apoptosis in A375 cells treated with 50 μM (IC 50 ) telmisartan and compared these results with those obtained after treatment with 100 μM (> IC 50 ) pioglitazone using the Annexin V/PI assay. Telmisartan increased both the early-apoptotic and late-apoptotic/necrotic fraction of the cells in a time-dependent manner, while pioglitazone showed no significant effects (representative graphs after 48 h of treatment; Figure 3E and quantification after 24 and 48 h Figure 3F ). Apoptosis was further confirmed by the measurement of a significantly increased percentage of cleaved caspase 3-positive cells by flow cytometry after 48 h of treatment with 50 μM telmisartan ( Figure 3G ).
Telmisartan induces generation of the reactive oxygen species (ROS) in melanoma cells
To examine the mode of apoptotic cell death, we first measured ROS generation after 24 h of telmisartan treatment in A375 cells using dichlorofluorescein diacetate (DCFDA), a fluorogenic dye that measures hydroxyl radicals, peroxyl radicals, and other ROS. Unlike pioglitazone or losartan, which at the concentration of 100 μM did not increase the oxidation of DCFDA to fluorescent DCF, 50 μM telmisartan increased the relative ROS levels in A375 cells, as measured by flow cytometry (representative graph Figure 4A and quantification Figure 4B ). Consistent with this finding, telmisartan also increased the levels of phosphorylated p38, a free radical sensor 27, 28 ( Figure 4C ). NADPH oxidase (NOX) and oxidative reactions on the mitochondrial membrane are the main sources of ROS. To examine the potential sources of ROS in telmisartan-treated cells, we measured the telmisartan-induced DCFDA fluorescence in the presence of reduced glutathione (L-GSH), N-actetyl-L-cysteine (synthetic precursor of GSH and cysteine, free radical scavenger), or apocynin (NADPH oxidase inhibitor). While 1 mM L-GSH or 10 mM NAC decreased the relative ROS levels in the telmisartan-treated cells, 100 μM apocynin did not prevent ROS generation ( Figure 4D) . These results imply that NADPH-dependent oxidases are not involved in telmisartan-induced ROS generation, and that the ROS generation is of mitochondrial origin. We confirmed the induction of ROS generation by telmisartan and its prevention by NAC in the BRAF WT melanoma cell line HTB140 ( Figure 4E) . A strong positive correlation exists between mitochondrial ROS release and mitochondrial membrane potential (ΔΨ) 29 ; therefore, we measured the ΔΨ by the flow cytometry analysis of Rhodamine123-stained cells. In telmisartan-treated A375 cells, the mitochondria were hyperpolarized, as seen by the loss of fluorescence, unlike the cells treated with pioglitazone, where pioglitazone had a limited effect on membrane potential even at a higher dose ( Figure 4F) .
Telmisartan alters melanoma cell bioenergetics
High glycolytic activity or impaired oxidative phosphorylation (OXPHOS) are possible sources of increased cellular ROS levels 30 . PPARγ is involved in glucose sensing 31 , and the PPARγ agonist pioglitazone exerts its antidiabetic activity by increasing the cellular glucose uptake 32 . We measured whether telmisartan too can affect glucose uptake in A375 cells, by measuring the uptake of the fluorescent glucose analogue 2-NBDG using flow cytometry. We observed that 50 μM telmisartan significantly increased the 2-NBDG uptake to a greater extent than pioglitazone at the same concentration, both shortly after its addition (measured at the 1 h time point) and after 24 h of treatment (Figure 5Ai representative graphs and 5Aii quantification).
Next, we measured the glycolytic rate by examining the glucose consumption and lactate production in A375 and HTB140 cells. As expected, treatment with 50 μM pioglitazone increased the glycolysis in A375 cells 33 . We observed an increase in glucose consumption per μg of cell protein ( Figure 5B ) and increased lactate production, measured by the decreased pH of the culture medium ( Figure 5C ). On the contrary, 50 μM telmisartan decreased the glucose consumption and did not change the extracellular acidification in A375 cells (Figure 5B and 5C) . This implies that in A375 cells, in the presence of telmisartan, glucose is taken up at a higher rate, but is not utilized at a higher rate. To determine whether the decreased consumption of glucose was the cause for the decreased cell viability, we tested the effects of telmisartan in A375 cells in the presence of excess glucose (25 mM, compared to 11 mM in standard RPMI) or in the presence of 2-deoxy-D-glucose (2DG), a glycolysis inhibitor. Increased glucose concentration did not ameliorate the effects of telmisartan (Figure 5D ), but as expected, it ameliorated the effects of 2DG on cell viability. Furthermore, telmisartan had additive effects with 2DG, as observed in the MTT assay ( Figure 5D) . In HTB140 cells, at a telmisartan concentration of 50 μM, a similar trend was observed in the glucose consumption and lactate excretion assays ( Figure 5E and 5F), but statistical significance was not observed. This is consistent with the observation of cytotoxic effects in HTB140 cells, which required higher doses of telmisartan ( Figure 3A and 3D) . Moreover, the basal level of glucose consumption was also lower in HTB140 cells than in A375 cells (Figure 5B and E) . Given that increased intracellular glucose uptake can induce mitochondrial fragmentation 34 that is causal for ROS production 35 , we examined the mitochondrial morphology in A375 and HTB140 cells after telmisartan treatment by the immunocytochemical analysis of the mitochondrial import receptor subunit TOM20. Treatment with 50 μM telmisartan, but not pioglitazone, for 24 h induced the fragmentation of mitochondria, as seen by the generation of mitospheres ( Figure 6A) . We confirmed mitochondrial fragmentation in telmisartan-treated cells by staining the cells with MitoTracker Red CMXRos, which accumulates in active mitochondria ( Figure 6B) . These results imply that in the presence of telmisartan, glucose is imported into cells, but not used for glycolysis and this could cause mitochondrial fragmentation and ROS release.
Telmisartan has synergistic effects with vemurafenib in vitro
In melanoma patients treated with the BRAF inhibitor 
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vemurafenib, there is a lack of durable response, and in vitro, there is incomplete apoptosis 36 . In recent years, targeting mitochondrial function to improve the response to BRAF/MAPK inhibitors and overcome resistance has shown promising results [37] [38] [39] . Therefore, we tested whether combination treatment with telmisartan can improve the efficacy of vemurafenib. To assess the cytotoxic effects of the drug combinations, we used the Chou-Talalay model 40 , which requires drugs to be administered at a fixed dose ratio. We treated A375 cells with a combination of telmisartan and vemurafenib in a 5 × 5 dose matrix, such that the telmisartan IC 50 to vemurafenib IC 50 ratio was 83:1, and measured the resultant cell viabilities by the MTT assay ( Figure 7A ). Isobologram analysis of the drug combination treatment at low concentrations and concentrations up to the IC 50 value revealed synergism (Figure 7C and 7D, CI = 0.325 to CI = 0.776); however, at high concentrations, slight antagonism was observed ( Figure 7B , CI = 1.04) ( Table 1) . Indeed, the addition of 25 μM telmisartan (½IC 50 ) to vemurafenib increased apoptosis in vemurafenib-treated cells ( Figure 7E representative graphs after 72 h of treatment and Figure 7F quantification). It has been reported that the inhibition of BRAF signaling leads to the fusion of mitochondrial networks 41 , with an increase in the mitochondrial length 42 .
To investigate the possible mechanism of the observed synergy, we examined the mitochondrial morphology in A375 cells. Telmisartan prevented the formation of mitochondrial filaments in vemurafenib-treated cells and 
Telmisartan is effective in vemurafenibresistant melanoma cells
As switching to oxidative metabolism in BRAF V600E mutant vemurafenib-resistant tumors is one of the main causes of targeted drug resistance, we examined whether cells from the vemurafenib-resistant BRAF V600E mutant cell line A375 are sensitive to telmisartan. We generated the A375R cell line by continuously growing parental A375 cells in the presence of increasing concentrations of vemurafenib, starting from IC 10 , until reaching 2 × IC 50 of the parental A375 (1 μM vemurafenib) with no detectable cell death. The resistant cell line had a shorter doubling time (18 h, compared to 24 h for the parental cell line, Figure 8A ) and five times higher IC 50 value for vemurafenib, as seen in the MTT test (3 μM, compared to 0.6 μM for the parental cell line, Figure 8B) . Analysis of the cell cycle showed that unlike the parental cell line, which in response to 0.5 μM vemurafenib showed an increase in the fraction of sub G 1 phase cells (late apoptosis) and a decrease in the fraction of S and G 2 /M phase cells after 72 h of treatment, the cell cycle distribution in A375R cells was not affected by vemurafenib treatment ( Figure 8C) . Nevertheless, the A375R cell line still responded to telmisartan, with an IC 50 of 35 μM, as observed in the MTT test (Figure 8D) , and showed the induction of ROS generation in the presence of telmisartan ( Figure 8E ). In addition, treatment with telmisartan sensitized the cells to vemurafenib, as shown by the increased apoptotic fraction of A375R cells treated with 25 μM telmisartan and 0.5 μM vemurafenib, compared to the treatment with either agent alone ( Figure 8F quantification and Figure 8G representative graphs of Annexin/PI assay). These results imply that telmisartan may revert the vemurafenib resistance acquired by melanoma cells.
Discussion
While metastatic melanoma remains an incurable disease, in recent years, immune-checkpoint inhibitors and targeted drugs have improved the progression-free and overall survival of melanoma patients 43 . Unfortunately, most responses to targeted therapy are transient due to the development of secondary mutations, upregulation of alternative signaling cascades, and metabolic adaptations. In this study, we tested the effects of telmisartan, which is an AGTR1 inhibitor and partial agonist of the PPARγ receptor, on melanoma cell viability. We found that the mRNA expression for both receptors is present in human melanoma samples and melanoma cell lines, with a trend of downregulation, compared to uninvolved skin. Losartan, a pure AGTR1 inhibitor, had no effects on cell viability; however, the effects of telmisartan also did not correlate with the PPARγ receptor expression. Various thiazolidinediones (PPARγ agonists) have been reported to inhibit the activity of OXPHOS complexes 44 independently of the PPARγ receptor 45 . In our study, telmisartan induced melanoma cell apoptosis, more efficiently in cells from BRAF mutant melanoma cell lines, which require constant glucose and glutamine sources for rapid proliferation and growth 46 . This implied that the cytotoxic effect of telmisartan is metabolism dependent. Melanoma cells have intrinsically high levels of oxidative stress due to their accelerated metabolism, which renders them more susceptible to oxidative stress-induced cell death than normal cells 47, 48 . We found that telmisartan induces the generation of ROS and alters the mitochondrial polarization and morphology. Telmisartan increased the glucose uptake, but failed to induce the increase in glycolysis. In addition to its role in energy production, glucose metabolism leads to the formation of pyruvate and NADPH, both of which function in the cellular detoxification of hydroperoxides. When glucose-stimulated ROS production, leading to further glucose uptake, is not adequately counterbalanced by (glucose-stimulated) ROS scavenging systems, a toxic cycle is triggered, ultimately leading to cell death 30 , which is what we observed in the telmisartan-treated melanoma cells. We hypothesize that the pro-apoptotic effects of telmisartan were PPARγ receptor-independent, as they did not correlate with the PPARγ expression levels, but were metabolic phenotype-dependent, as the effects of telmisartan did correlate with the BRAF status. Consistent with this, the combination of telmisartan and vemurafenib had synergistic effects in vitro. The addition of a low dose of telmisartan increased apoptosis in vemurafenib-treated cells and induced mitochondrial fragmentation. Synergy with vemurafenib could be argued by the prevention of mitochondrial fusion that happens upon vemurafenib treatment as a strategy to compensate for the inhibition of glycolysis 39 . The proposed mechanism of telmisartan action is depicted in Supplementary Figure S2 . In addition, telmisartan treatment was effective in vemurafenib-resistant A375R cells; more importantly, telmisartan treatment sensitized these cells to vemurafenib. Specific PPARγ agonists have been previously reported to have anti-melanoma effects 10 , with these effects being mediated through PPARγ 11, 49 . They have also been reported to act at the mitochondrial level, independent of the PPARγ protein level, when administered at higher doses 12 .
Unfortunately, clinical monotherapy trials with PPARγ agonists were hindered by studies showing pro-angiogenic and pro-tumorigenic effects of direct PPARγ agonists 50 . However, the extent of the PPARγ-mediated transcription stimulated by telmisartan is one-third of that stimulated by glitazones 51 , and the binding of telmisartan to PPARγ results in a different gene expression profile 52 . In our study, telmisartan showed pro-apoptotic effects at lower doses when compared to the direct agonist pioglitazone, and with a distinct mechanism. In healthy individuals, the maximum steady-state plasma level of telmisartan after the oral intake of 320 mg of telmisartan is 20 μM in males 53 and the plasma concentrations of telmisartan are generally 2-3 times higher in females than in males 54 . Therefore, effective doses of telmisartan examined in vitro can be administered to patients. Our findings provide a rationale for retrospective studies aiming to determine whether telmisartan influences the progression, therapy outcome, and mortality rate in melanoma patients. 
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